Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | SPHK2 | Q9NRA0 | 5/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 5/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | SRC | P12931 | 8/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30020662 | 1.00 | ABCB1 (0.47) | ABCB1SPHK2SPHK1S1PR1S1PR3 | |
| SCHEMBL18668583 | 0.86 | S1PR1 (0.46) | SPHK2SPHK1S1PR1S1PR3S1PR4 | |
| SCHEMBL18668584 | 0.86 | S1PR1 (0.46) | SPHK2SPHK1S1PR1S1PR3S1PR4 | |
| SCHEMBL16397875 | 0.86 | ABCB1 (0.43) | ABCB1GPR119SRC | |
| SCHEMBL21996640 | 0.84 | ABCB1 (0.48) | ABCB1GPR119SRC | |
| SCHEMBL71548 | 0.84 | ABCB1 (0.58) | ABCB1GPR119SRC | |
| SCHEMBL3855580 | 0.84 | ABCB1 (0.58) | ABCB1GPR119SRC | |
| SCHEMBL30421047 | 0.84 | ABCB1 (0.58) | ABCB1GPR119SRC | |
| SCHEMBL28995867 | 0.84 | ABCB1 (0.58) | ABCB1GPR119SRC | |
| SCHEMBL7327353 | 0.84 | ABCB1 (0.58) | ABCB1GPR119SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230122855-A1 | Synthetic Sphingolipid-Like Molecules, Drugs, Methods of Their Synthesis and Methods of Treatment | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-04-20 | — | — | US | disclosed |
| US-11479530-B2 | Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11479530-B2 | Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment | SGMS1, SGMS2, SMPD1 | ABCB1 2379/4885SPHK2 4/4885SPHK1 6/4885 |
| US-20230122855-A1 | Synthetic Sphingolipid-Like Molecules, Drugs, Methods of Their Synthesis and Methods of Treatment | SGMS1, SGMS2, SMPD1 | ABCB1 2379/4885SPHK2 4/4885SPHK1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.